The Plk1 inhibitor BI 2536 temporarily arrests primary cardiac fibroblasts in mitosis and generates aneuploidy in vitro.
BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under clinical development for cancer therapy. The effect of this drug on cancer cells has been extensively investigated, but information about the effects on primary dividing cells and differentiated non-divi...
Main Authors: | Bo Lu, Hasan Mahmud, Alexander H Maass, Bo Yu, Wiek H van Gilst, Rudolf A de Boer, Herman H W Silljé |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2945759?pdf=render |
Similar Items
-
Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels
by: Jörg Haupenthal, et al.
Published: (2012-05-01) -
Y(4626) as a molecular state from interaction $${D}^*_s{\bar{D}}_{s1}(2536)-{D}_s{\bar{D}}_{s1}(2536)$$ Ds∗D¯s1(2536)-DsD¯s1(2536)
by: Jun He, et al.
Published: (2020-03-01) -
Observation of D_s1(2536)^+ → D^+π^-K^+ and angular decomposition of D_s1(2536)^+ →D^*+K_S^0
by: Balagura, V., et al.
Published: (2008) -
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
by: van Gilst Wiek H, et al.
Published: (2011-09-01) -
PLK1 Activation in Late G2 Sets Up Commitment to Mitosis
by: Lilia Gheghiani, et al.
Published: (2017-06-01)